Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum NetraMark Holdings Inc AINMF


Primary Symbol: C.AIAI

NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several... see more

CSE:AIAI - Post Discussion

NetraMark Holdings Inc > $MEND.c Receives High Recognition For Its AI-Based Platform
View:
Post by partystocker on Mar 12, 2022 12:03pm

$MEND.c Receives High Recognition For Its AI-Based Platform

Nusosene (CSE: MEND) has received further recognition validating its AI-based platform.


$MEND.c CSO recently received the “Highly Cited Paper” award from the peer-reviewed journal Exploration of Medicine for his research supporting $MEND.c’s platform's ability to accurately stratify patient subpopulations, even within relatively small study samples. 


This research strongly validates Nurosene's AI platform and provides novel insights into Alzheimer's disease, which has a diagnostics and therapeutics market valued at US$7 billion.


$MEND.c is currently on a bounce from all-time lows, approaching a retest of the 50MA. Shares are currently trading at $.6 and the company is valued at $24.17 million. 


https://ceo.ca/@newswire/nurosenes-cso-and-director-of-bioinformatics-receives

 
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities